Cystic fibrosis (CF) is a complex genetic disorder that primarily affects the respiratory and digestive systems, leading to chronic lung inflammation, pathogen infections, and digestive problems. In the lungs, this is also accompanied by chronic pathogen infections. Despite significant advancements, many animal models fail to fully replicate the complexity and progression of CF in humans. This limitation highlights the crucial need for innovative in-vitro approaches to improve CF research. Moreover, with the “FDA Modernization ACT 2.0” the use of complex in vitro cultures has been approved for drug testing in alternative to animal models.
In particular, 3D in vitro models, such as organoids and organ-on-a-chip technology, are promising in elucidating inflammatory processes and enhancing drug delivery prediction, potentially revolutionizing CF treatment strategies.
In this Research Topic, we invite submissions of Original Research, Methods and Review articles addressing various aspects of CF, with a focus on novel in-vitro models for CF research. Of particular interest are papers exploring 3D in vitro models, which offer a promising platform for studying inflammation dynamics and improving drug delivery strategies.
In detail, topics may include but are not limited to the following themes:
• Development of novel in vitro models for CF research
• Characterization of CF pathophysiology using in vitro systems
• Evaluation of drug efficacy and toxicity using in vitro CF models
• Translation of in vitro findings to clinical applications
We look forward to your contributions and the opportunity to advance CF research.
Keywords:
cystic fibrosis, 3D in vitro models, novel in vitro models, drug efficacy, drug toxicity, clinical applications, drug delivery, organoids, organ-on-a-chip
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Cystic fibrosis (CF) is a complex genetic disorder that primarily affects the respiratory and digestive systems, leading to chronic lung inflammation, pathogen infections, and digestive problems. In the lungs, this is also accompanied by chronic pathogen infections. Despite significant advancements, many animal models fail to fully replicate the complexity and progression of CF in humans. This limitation highlights the crucial need for innovative in-vitro approaches to improve CF research. Moreover, with the “FDA Modernization ACT 2.0” the use of complex in vitro cultures has been approved for drug testing in alternative to animal models.
In particular, 3D in vitro models, such as organoids and organ-on-a-chip technology, are promising in elucidating inflammatory processes and enhancing drug delivery prediction, potentially revolutionizing CF treatment strategies.
In this Research Topic, we invite submissions of Original Research, Methods and Review articles addressing various aspects of CF, with a focus on novel in-vitro models for CF research. Of particular interest are papers exploring 3D in vitro models, which offer a promising platform for studying inflammation dynamics and improving drug delivery strategies.
In detail, topics may include but are not limited to the following themes:
• Development of novel in vitro models for CF research
• Characterization of CF pathophysiology using in vitro systems
• Evaluation of drug efficacy and toxicity using in vitro CF models
• Translation of in vitro findings to clinical applications
We look forward to your contributions and the opportunity to advance CF research.
Keywords:
cystic fibrosis, 3D in vitro models, novel in vitro models, drug efficacy, drug toxicity, clinical applications, drug delivery, organoids, organ-on-a-chip
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.